CAS No.: 230615-23-3
Varenicline HCl/盐酸伐尼克兰 Catalog No. CSN10132
Synonyms: CP 526555 hydrochloride;CP-526555 HCl
Varenicline HCl is a nicotinic receptor partial agonist and it stimulates nicotine receptors more weakly than nicotine itself does.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT01574703 Smoking Cessation Phase 4 Completed - - NCT02744417 Periodontitis Not Applicable Completed - - NCT02582008 Current Smoker ... more >> Head and Neck Squamous Cell Carcinoma Hypopharyngeal Squamous Cell Carcinoma Laryngeal Squamous Cell Carcinoma Nasopharyngeal Carcinoma Oral Cavity Squamous Cell Carcinoma Oropharyngeal Squamous Cell Carcinoma Collapse << Early Phase 1 Recruiting January 2020 United States, North Carolina ... more >> Wake Forest University Health Sciences Recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Mercedes Porosnicu 336-716-8664 mporosni@wakehealth.edu Principal Investigator: Mercedes Porosnicu United States, South Carolina Medical University of South Carolina Not yet recruiting Charleston, South Carolina, United States, 29425 Contact: Graham Warren 843-876-2295 warrengw@musc.edu Principal Investigator: Graham Warren Collapse << - 更多
- 参考文献
- [1] Cinciripini PM, Robinson JD, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013 May;70(5):522-33.
- [2] Nides M, Oncken C, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006 Aug 14-28;166(15):1561-8.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 230615-23-3 | 储存条件 |
|
|
| 分子式 | C13H14ClN3 | 运输 | 蓝冰 | |
| 分子量 | 247.72 | 别名 | CP 526555 hydrochloride;CP-526555 HCl |
